News - BioSpace
网页Alina Zahid. Load More. BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The latest biotech and pharmaceutical news from BioSpace.
Biotech and Pharma Industry News | BioPharma Dive
网页23andMe’s independent board directors resign. In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
网页2024 Q2 Job Market Report: More People Competing for Fewer Job Openings. For the second quarter of 2024, there were 25% fewer jobs posted live on BioSpace compared to the same quarter of 2023. The year-over-year job response rate rose from 14.6% to …
The biopharma industry outlook on 2024: Guarded optimism for a …
网页Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
Investors put $400M into biotech licensing obesity drugs from China
网页2024年5月16日 · Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a disclosure posted on the Shanghai Stock Exchange Thursday. The newly created company, currently referred to as “Hercules CM NewCo ...
5 questions facing emerging biotech in 2024 - BioPharma Dive
网页2024年1月8日 · 5 questions facing emerging biotech in 2024. The sector’s recent momentum will be tested by a prolonged funding pullback and concerns that regulators may challenge early partnership deals. Ask a biotechnology company executive, investor or analyst how they feel about the sector in 2024, and …
Biotech M&A has plateaued. Track the deals that are happening …
网页2024年9月18日 · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More …
网页5 天之前 · Aurinia Pharmaceuticals announced plans to cut at least 25% of its workforce this quarter after the company failed to find a buyer, Fierce Biotech reported. The Canadian biotech firm is trimming its drug pipeline, eliminating work on its AUR200 compound for B-cell mediated autoimmune conditions and its AUR300 M2 macrophage regulator.
Q1 2021: A Look at Top 25 Biopharma Companies by Market Cap
网页2021年5月2日 · Pfizer expects to bring in $15 billion from the vaccine in 2021, which would greatly contribute to the $59 billion to $61 billion it expects to earn overall for the year. Abbott $213.19 billion. The pharma giant of the Midwest kicked off 2021 strong, announcing $10.5 billion in sales, a growth rate of 35.3 percent in Q1.
Recursion’s Chris Gibson on AI in biotech and ‘virtuous cycles’
网页Published Jan. 12, 2024. Gwendolyn Wu Reporter. Laboratory space at Salt Lake City-based Recursion. Permission granted by Recursion Pharmaceuticals. Chris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. At a J.P. Morgan Healthcare Conference reception …